Corcept Therapeutics reported that its Phase 3 ROSELLA study of relacorilant plus nab‑paclitaxel in patients with platinum‑resistant ovarian cancer met the overall‑survival primary endpoint, showing a 35 % reduction in the risk of death compared with nab‑paclitaxel alone. The hazard ratio of 0.65 and a p‑value of 0.0004 confirm the statistical significance of the finding, while the median overall survival increased from 11.9 months in the control arm to 16.0 months in the relacorilant arm—a 4.1‑month improvement that exceeds the study’s pre‑specified threshold.
The trial’s success builds on a previously reported 30 % reduction in disease‑progression risk, reinforcing relacorilant’s safety profile and its potential as a combination partner in oncology. The 381‑patient study demonstrates that adding relacorilant to standard chemotherapy can translate into a clinically meaningful survival benefit in a population with limited treatment options, positioning the drug as a candidate for regulatory approval in a high‑need market.
Corcept’s financial outlook is tempered by a recent regulatory setback: the company received a Complete Response Letter from the FDA for relacorilant in hypercortisolism on December 31, 2025, which weighed on investor sentiment. Despite this, the company’s 2025 revenue guidance of $800 million to $850 million remains above analyst expectations, and its 2024 revenue of $675 million grew 40 % year‑over‑year, underscoring the strength of its core product portfolio. The oncology milestone is expected to offset headwinds from the hypercortisolism program and support the company’s projected $3 billion to $5 billion annual revenue from relacorilant over the next 3‑5 years.
Investors reacted positively to the clinical data, with market participants highlighting the milestone’s potential to de‑risk the oncology program and broaden the drug’s indication. The announcement also reinforced confidence in the company’s ability to navigate regulatory challenges, as reflected in the continued optimism around its future pipeline.
Dr. Alexander Olawaiye, principal investigator of the ROSELLA trial, said the addition of relacorilant to nab‑paclitaxel “positions the combination as a new standard‑of‑care treatment for patients with platinum‑resistant ovarian cancer,” emphasizing the therapeutic impact of the survival benefit.
Looking ahead, the company plans to submit a marketing application for relacorilant in ovarian cancer, leveraging the overall‑survival data to support a broader regulatory strategy. The trial’s outcome also strengthens the case for exploring relacorilant in other solid tumors, potentially expanding the drug’s market reach and reinforcing Corcept’s long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.